<DOC>
	<DOCNO>NCT01567163</DOCNO>
	<brief_summary>The purpose study assess effect concomitant ramucirumab pharmacokinetics docetaxel participant advance malignant solid tumor . Participants complete Cycle 1 , Day 1 , Cycle 2 , Day 1 accord schedule replace purpose analysis ; participant may continue receive study therapy . No dose reduction , delay miss dos allow Cycles 1 2 .</brief_summary>
	<brief_title>A Study Ramucirumab Docetaxel Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant histologic cytologic documentation malignant solid tumor Participant advance solid tumor resistant standard therapy standard therapy available Participant 01 prior taxanecontaining treatment regimen ( include taxane monotherapy ) , must complete least 6 month first dose study medication . Prior bevacizumab allow . Participant resolution Grade ≤ 1 ( except otherwise state eligibility criterion ) National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 ( NCICTCAE v 4.0 ) clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy Participant Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 Participant adequate hematologic function ( absolute neutrophil count [ ANC ] ≥ 1500 cells/liter ( cells/L ) , hemoglobin ≥ 10 grams/deciliter ( g/dL ) , platelet count ≥ 100,000 cells/microliter ( cells/mcL ) ] . Blood transfusion allow must complete 48 hour study drug administration . Participant adequate hepatic function ( bilirubin ≤ 1.5 time upper limit normal [ x ULN ] , aspartate transaminase [ AST ] alanine transaminase [ ALT ] ≤ 1.5 x ULN ) Participant serum creatinine ≤ 1.5 x ULN . If serum creatinine &gt; 1.5 x ULN , calculate creatinine clearance [ CrCl ] ≥ 40 milliliters/minute ( mL/min ) Participant 's urinary protein &lt; 2+ dipstick routine urinalysis ( UA ) study entry Participant must adequate coagulation function define international normalized ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) activate PTT ( aPTT ) ≤ 1.5 x ULN Women childbearing potential must negative serum urine pregnancy test . Eligible participant reproductive potential ( sex ) agree use adequate method contraception study period 12 week last dose study medication . Has know allergy hypersensitivity treatment component Are currently enrol , discontinue within last 14 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Has receive therapeutic monoclonal antibody within 42 day prior first dose study medication Has receive radiotherapy within 14 day prior first dose study medication Has receive cytotoxic chemotherapy within 21 day prior first dose study medication Is receive concurrent treatment another anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy ( except androgen deprivation therapy prostate cancer ) , radiation therapy , chemoembolization , target investigational anticancer therapy Is receive chronic therapy nonsteroidal antiinflammatory agent antiplatelet agent . ( Aspirin use dose 325 milligrams/day ( mg/day ) analgesic agent low bleed risk permit . ) Has history uncontrolled hereditary acquire bleed thromboembolic disorder Has experience arterial thromboembolic event , include myocardial infarction ( MI ) , unstable angina , stroke transient ischemic attack ( TIA ) , within 6 month prior first dose study medication Has history deep vein thrombosis , pulmonary embolism , significant thromboembolism 3 month prior first dose study medication Has experience Grade 3 4 hemorrhagic event within 3 month prior first dose study medication Has experience peripheral neuropathy ≥ Grade 2 time prior study entry Has bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection , Crohn 's disease , ulcerative colitis , chronic diarrhea History gastrointestinal perforation and/or fistula within 6 month prior randomization Has ongoing active infection require treatment intravenous antibiotic Has serious nonhealing wound , peptic ulcer , bone fracture within 28 day prior first dose study medication Has uncontrolled hypertension despite standard medical management Has symptomatic congestive heart failure , symptomatic poorly control cardiac arrhythmia , serious , uncontrolled medical disorder , opinion investigator would make participant ineligible participation study Has know brain leptomeningeal metastasis Has know positive status human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndromerelated illness Has know active drug alcohol abuse Has pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen Has major surgery within 28 day prior first dose study medication subcutaneous venous access device implantation within 7 day prior first dose study medication Has elective plan major surgery course trial If primary cancer nonsmallcell lung cancer ( NSCLC ) , radiographic evidence intratumor cavitation , major blood vessel invasion encasement cancer , proximity cancer major airway Has receive prior ramucirumab ( IMC1121B ) therapy Is receive concomitant therapy clinically relevant inhibitor inducer cytochrome P450 3A4 3A5 and/or isoenzymes Has cirrhosis level ChildPugh B ( bad ) , cirrhosis history hepatic encephalopathy , ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Advanced Malignant Solid Tumors</keyword>
</DOC>